Moxetumomab pasudotox (Lumoxiti)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Mechanism of action

A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38)

Preliminary data

Hairy cell leukemia

  1. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. 2012 May 20;30(15):1822-8. Epub 2012 Feb 21. PubMed

Also known as

  • Code name: CAT-8015
Retrieved from "https://hemonc.org/w/index.php?title=Moxetumomab_pasudotox_(Lumoxiti)&oldid=19376"